secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coya Therapeutics, Inc. (COYA)
CIK:        0001835022
Form:       8-K
Filed at:   2025-07-29T23:59:59+00:00
Accession:  0001193125-25-168115
Event type: regulatory
Sentiment:  neutral
Materiality: 0.45
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA delays IND review for COYA 302 ALS trial due to workload; decision expected by Aug 29, 2025
--------------------------------------------------------------------------------

- Coya submitted IND for Phase 2 ALS study of COYA 302 on June 30, 2025.
- FDA informed Coya on July 29, 2025, that it cannot meet initial July 30 review goal due to workload and resource constraints.
- FDA expects to provide IND decision no later than August 29, 2025.
- Delay affects timeline for starting the planned 24-week placebo-controlled study with 24-week OLE.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835022/000119312525168115/0001193125-25-168115-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835022/000119312525168115/d14950d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-168115

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer